Thiazide blood pressure medications have been unknowingly targeting the endocannabinoid system for decades

A discovery that thiazide diuretics work partly through the endocannabinoid system reveals that physicians have been modulating this system in hypertension patients for over sixty years without knowing it.

Garau, Gianpiero·American journal of hypertension·2025·Moderate EvidenceNarrative Review
RTHC-06502Narrative ReviewModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Narrative Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

The phospholipase NAPE-PLD was identified as a systemic target of thiazide diuretics, meaning these common blood pressure medications produce their chronic therapeutic effects partly by generating anandamide and other protective lipid signaling molecules through the endocannabinoid system.

Key Numbers

Over sixty years of clinical thiazide use. CB1 agonists caused hypotension but risked tachycardia, heart, and kidney damage. FAAH inhibitors normalized blood pressure in hypertensive rats.

How They Did This

State-of-the-art narrative review synthesizing thirty years of research on endocannabinoid system modulation for hypertension, including the author's discovery of NAPE-PLD as a thiazide target.

Why This Research Matters

This reframes our understanding of one of the most widely prescribed classes of blood pressure medication. Knowing that thiazides work partly through the endocannabinoid system opens the door to designing more targeted cardiovascular therapies.

The Bigger Picture

Previous attempts to directly target the endocannabinoid system for cardiovascular disease were derailed by side effects. The thiazide-NAPE-PLD discovery suggests a subtler, clinically validated approach to ECS modulation has been hiding in plain sight.

What This Study Doesn't Tell Us

As a narrative review, this reflects a selective synthesis rather than a systematic evaluation of all evidence. The NAPE-PLD mechanism is relatively new and requires further validation.

Questions This Raises

  • ?Could new drugs targeting the NAPE-PLD thiazide-binding site offer better cardiovascular protection with fewer side effects?
  • ?Do individual differences in endocannabinoid system function explain why some patients respond better to thiazides?

Trust & Context

Key Stat:
that clinicians have unknowingly modulated the endocannabinoid system through thiazide prescriptions
Evidence Grade:
Well-supported mechanistic discovery backed by decades of clinical thiazide use, though the specific NAPE-PLD pathway requires further clinical validation.
Study Age:
2025 publication.
Original Title:
State of the Art Review: Thiazide diuretics exploit the endocannabinoid system via NAPE-PLD.
Published In:
American journal of hypertension (2025)
Database ID:
RTHC-06502

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research without a strict systematic method.

What do these levels mean? →

Frequently Asked Questions

What is NAPE-PLD?

NAPE-PLD is a membrane enzyme that generates anandamide (an endocannabinoid) and other lipid signaling molecules. The discovery that thiazide diuretics bind to and stabilize this enzyme explains both their immediate diuretic effect and their long-term cardiovascular protection.

Why did earlier attempts to target the endocannabinoid system for blood pressure fail?

Direct CB1 receptor agonists lowered blood pressure but caused dangerous side effects including rapid heart rate and organ damage. CB1 blockers developed for obesity also had serious psychiatric side effects. Thiazides achieve ECS modulation more subtly through NAPE-PLD.

Read More on RethinkTHC

Cite This Study

RTHC-06502·https://rethinkthc.com/research/RTHC-06502

APA

Garau, Gianpiero. (2025). State of the Art Review: Thiazide diuretics exploit the endocannabinoid system via NAPE-PLD.. American journal of hypertension. https://doi.org/10.1093/ajh/hpaf174

MLA

Garau, Gianpiero. "State of the Art Review: Thiazide diuretics exploit the endocannabinoid system via NAPE-PLD.." American journal of hypertension, 2025. https://doi.org/10.1093/ajh/hpaf174

RethinkTHC

RethinkTHC Research Database. "State of the Art Review: Thiazide diuretics exploit the endo..." RTHC-06502. Retrieved from https://rethinkthc.com/research/garau-2025-state-of-the-art

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.